Research library

D

grade

GLP-1 receptor agonists show promise in managing type 2 diabetes and obesity, but their long-term safety and effectiveness require ongoing evaluation.

summary

A

grade

Retatrutide significantly reduced the apnea-hypopnea index in adults with obstructive sleep apnea compared to placebo, particularly at the 9 mg dose.

-34.3 events/hour AHI change with 9 mg retatrutide vs -9.9 with placebo in TRIUMPH-1-OSA, difference vs placebo -24.4 (95% CI, -34.1 to -14.7)

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

A

grade

Retatrutide shows promise as a weight loss medication, particularly in higher doses, but further details on efficacy and safety are needed for clinical application.

Not reported in abstract.

summary

D

grade

Retatrutide is a triple agonist that shows promise for weight loss in patients with obesity, with a safety profile similar to existing treatments.

Not reported in abstract.

summary

A

grade

Retatrutide showed significant weight loss in adults with obesity and type 2 diabetes compared to placebo over 80 weeks, but further research is needed to understand long-term outcomes.

-18.8% bodyweight change at week 80 with retatrutide 12 mg, n=287, p<0.0001.

summary

A

grade

Retatrutide significantly reduced body weight and improved knee pain and sleep apnea events in adults with obesity over 80 weeks. However, the clinical relevance of these findings should be considered in the context of individual patient circumstances.

-25.0% mean percent change in body weight for 12 mg dose vs -3.9% placebo, P<0.001

summary

D

grade

Not reported in abstract.

summary

B

grade

A 29-year-old man with Prader-Willi syndrome lost 108.7 kg over 18 months using sequential incretin-based therapy, but this is a single case report and results may not be generalizable.

Total weight loss of 58.8% (-108.7 kg) at 18 months.

summary

C

grade

The combination of retatrutide and cagrilintide shows promise for enhancing weight loss and metabolic outcomes in a rodent model, but further research is needed to determine its relevance to human obesity treatment.

Not reported in abstract.

summary

D

grade

GLP-1 receptor agonists may influence the oral microbiome in patients with obstructive sleep apnea, but the clinical implications are not yet clear.

Not reported in abstract.

summary

C

grade

The combination of retatrutide and cagrilintide shows promise in enhancing weight loss and metabolic outcomes in obese male rats, but further research is needed to confirm these effects in humans.

Not reported in abstract.

summary

B

grade

Plasma is a more suitable matrix for detecting retatrutide than urine, with a detection window of approximately 56 days after administration.

Limits of detection (LOD) were 6.14 ng/mL in plasma and 2.44 ng/mL in urine.

summary

B

grade

Plasma is a more suitable matrix for detecting retatrutide than urine, with a detection window of approximately 56 days post-administration.

Limits of detection in plasma were 6.14 ng/mL and in urine were 2.44 ng/mL.

summary

D

grade

Glycemic control accounts for less than 20% of cardiovascular event reduction with incretin therapies, indicating other mechanisms are significant.

Glycemic improvement accounts for less than 15 to 20 percent of the reduction in major adverse cardiovascular events.

summary

D

grade

This study presents a validated LC-HRMS method that can accurately quantify GLP-1 receptor agonists, including retatrutide, with high sensitivity and specificity.

Mean recoveries of 113.7-118.4% for marketed formulations.

summary

B

grade

Clinicians should be aware of the potential risks associated with unregulated peptides like retatrutide, especially in patients with type 1 diabetes, where management can be complicated by concurrent illnesses.

Peak ketonaemia reached 4.3 mmol/L.

summary

D

grade

Not reported in abstract.

summary

B

grade

Retatrutide increased the force of contraction in isolated human atrial preparations, but its clinical relevance and implications for patient care remain unclear.

Cumulatively applied retatrutide starting at 10 nM elevated FOC in HAP in a concentration- and time-dependent manner.

summary

B

grade

Retatrutide use outside of clinical trials is associated with less than half the weight loss seen in trials and significant cardiovascular symptom burden.

7.2% body weight loss at 6-12 months for compounded retatrutide users, n=531, P=0.004.

summary

A

grade

Retatrutide treatment was associated with significant reductions in several cardiovascular risk biomarkers in adults with obesity, but the clinical implications of these findings require further investigation.

High-sensitivity C-reactive protein was reduced by -54.8% in Study 2.

summary

D

grade

Current evidence suggests a potential link between GLP-1 receptor agonists and neuropsychiatric disorders, but causality has not been established.

Not reported in abstract.

summary